Avidity Buys $7.19M ELVN Shares, Boosts Stake

Avidity Partners Management recently invested $7.19 million in Enliven Therapeutics, increasing their stake to 3.73% and making it their fifth largest holding. Enliven, a clinical-stage biotech, is developing small molecule kinase inhibitors for cancer treatments. Their lead candidate, ELVN-001, targets chronic myeloid leukemia, while ELVN-002 focuses on HER2-mutant tumors. Both are in phase one trials. Enliven plans to release phase one data for ELVN-001 by mid-2026 and start the pivotal phase three ENABLE-2 trial in the second half of this year. Despite risks, Aviditys investment indicates confidence in Enlivens oncology pipeline. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/6c1138e8402aeda3